anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An anti-anaemic substance is separated in concentrated form from extracts of liver, spleen or other organs by lixiviation with phenol cresol or other phenolic solvents which have been liquefied, if necessary, by heating or by addition of a liquefying agent such as a small percentage of water.  In a modification the active substance is adsorbed from the extract by means of active carbon, silica gel, fuller's earth or the like and the adsorbate is lixiviated with a phenolic substance.  The active substance is recovered from the phenol by precipitation with a relatively large volume of a water miscible liquid such as alcohol or acetone, or a liquid, such as ether or chloroform, which is miscible with the phenol but not with water may be added and the active substance thereupon extracted with water.  The lixiviation with phenol is preferably carried out at pH 6,5 to 8, but may be conducted fractionally by starting at a strongly acid reaction and neutralizing in successive steps, or by addition of a blocking agent, such as formaldehyde, and gradually eliminating this by addition of suitable reagents.  An aqueous extract from which only ballast substance have been removed by fractional lixiviation with phenol may be further treated by known methods.  The initial extract may have previously been treated to remove proteins, as by precipitation with alcohol.  When a dry extract is treated the phenolic solution obtained is preferably washed with water whereby certain dissolved ballast substances are removed.  In the case of an adsorbate this may be prepared in presence of a dilute solution of a phenol or may be washed with such a solution prior to lixiviation with concentrated phenol.  In a further modification an aqueous liver extract is acidified, treated with excess of warm acidic phosphotungstic acid, or an equivalent such as phosphomolybdenic acid or arsenomolybdenic acid, and cooled; the precipitate formed is separated, dissolved by addition of alkali to adjust the pH to 7 to 8 and the solution lixiviated with phenol.
Up to one third of patients with epilepsy progress to drug resistant epilepsy (DRE). Current treatment options for DRE include epileptic surgery and dietary therapy. Classic KD (Ketogenic diet) is the most studied dietary therapy but the stringent restrictions and practical difficulty makes it difficult to follow. So less restrictive diets like MAD and LGIT were introduced. These are reported to have less adverse effects also. But no published study has ever been conducted comparing these two diets head to head.
PURPOSE:To prepare a curable compsn. which cures rapidly, is excellent in curability and discoloration resistance, and forms, when cured, a slippery surface by compounding a specific polymerizable monomer with a volatile compd. and a polymn. initiator. CONSTITUTION:100pts.wt. at least one polymerizable monomer selected from the group consisting of polymers of formulas I, II, and III (wherein n is 0-3; R is H or methyl; R' is a group of formula IV or V; and R'' is a group of formula V), 20-400pts.wt. volatile compd., and a polymn. initiator in an amt. of 0.1-10wt.% of the sum of the polymerizable monomer and volatile compd. are compounded to give the title compsn. which cures rapidly even in the presence of oxygen to form a slippery surface, is excellent in hardness and discoloration resistance, and can be widely used in industry as a surface lubricant, exhibiting an esp. excellent effect in dental fields.
INTRODUCTION/AIMS: Randomized controlled trials show that repeat intravenous immunoglobulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barre Syndrome (GBS) non-responders. Furthermore, the delineation between GBS and Acute Onset CIDP (A-CIDP) can be particularly challenging and carries therapeutic implications. We aimed to evaluate the presence of repeat IVIG, combination therapy, and diagnostic reclassification from GBS to CIDP.
METHODS: We performed a retrospective study of a large healthcare database for patients with GBS in the US from 2001 to 2018. We identified individuals initially diagnosed with GBS and later re-classified as CIDP. Multivariable logistic regression models were developed to determine associations between patient factors and repeat IVIG dosing, combination therapy, and diagnostic re-classification from GBS to CIDP.
RESULTS: We identified 2325 patients with GBS. A total of 39.7% received repeat IVIG and 6.1% received combination therapy. The proportion of individuals initially diagnosed with GBS and then re-classified as CIDP was 32.0%. Repeat IVIG, combination therapy, and diagnostic reclassification remained stable over time. Female sex (OR 0.79, 95% CI 0.65-0.96) and medium-high net worth (OR 0.64, 95% CI 0.45-0.90) associated with repeat IVIG therapy, while Asian ethnicity associated with diagnostic re-classification from GBS to CIDP (OR 1.77, 95% CI 1.09-2.86).
DISCUSSION: Repeat IVIG dosing was quite common in GBS before newer trials suggesting harm in non-responders, and IVIG/PLEX combination therapy continues to persist despite strong evidence against use in non-responders. Further, nearly one in three patients initially diagnosed with GBS is subsequently diagnosed with CIDP, but the reasons are unclear.
The proposed study, a 3-arm randomized control trial (RCT), would be tested with 66 patients at Philadelphia VA with BMIs between 30 and 40. Participants in the control group would receive usual care from their providers and monthly weigh ins. Participants in the incentive conditions will receive daily monitoring of their weights for 32 weeks, plus a package of financial incentives if they lose weight. Incentive group subjects will be given a weight loss target of 24 lbs in the first 24 weeks and will be able to choose a weight loss goal of 0, 0.5, or 1 lb per week for the final two months of the study. Financial incentives in the first deposit contract condition will consist of a potential payment for every day they are under their target weight which consists of the prorated daily amount of their deposit contract plus an equal 1:1 match provided by the study team for the first 6 months framed as 'weight loss period' and then for 2 months framed as 'maintenance of weight loss'. In the second deposit condition, the incentive consists of 8 months of the prorated daily amount of their deposit contract plus a 1:1 match (without the framing of 'weight loss' vs 'maintenance of weight loss'). We will have 80% power to find a 5 kg difference in weight loss between the intervention and control groups. Subjects who lose more than 20 pounds in either of the intervention groups will be eligible for an additional incentive.

The proposed interventions will serve as the basis for a larger-scale intervention study of incentives for weight loss and maintenance that has the potential to substantially reduce the health burden of obesity among veterans.
The invention provides a solution for treating eye diseases and application thereof as well as an eye pad and a manufacturing method thereof, and relates to the technical field of eye care. The solution for treating the eye diseases comprises 20-30 parts by weight of N-acetyl-D-glucosamine and 4000-4500 parts by weight of water and has good eye care effect. The invention also provides the application of the solution for treating eye diseases in the preparation of eye ointment. The eye pad comprises a medical non-weaving compress which is soaked in the solution for treating the eye diseases and has health care, treatment and recovery effects on the eye diseases. The manufacturing method of the eye pad comprises the step of soaking the medical non-weaving compress in the solution for treating the eye diseases for at least 20 minutes. The manufacturing method adopts a simple technological process and is convenient to operate.
The invention discloses bacteroides fragilis BFS17 for relieving irritable bowel syndrome and intestinal canal hypersensitivity and application thereof. Bacteroides fragilis BFS17, accession number is GDMCC No:63172. the beneficial effects of the invention are as follows: 1. the bacteroides fragilis BFS17 can efficiently synthesize the probiotic GABA. 2. Obviously reduces the inflammatory level of intestinal cells and enhances the barrier function of intestinal tracts in vivo and in vitro. 3. Compared with probiotics approved clinically for IBS treatment, the invention can better relieve IBS symptoms, intestinal canal hypersensitivity and intestinal canal disorder related anxiety depression. 4. The invention has the advantages of convenient and safe use, no potential harm to human body in the multi-level verification of genes, cells and animals, safety and high efficiency. 5. The invention can regulate intestinal disorder strains and improve the content of beneficial metabolites in serum.
FujiCEM 2 (GC, Tokyo, Japan) was evenly distributed to the inner surface of the crown with the syringe and immediately placed onto the teeth with finger pressure. The crowns were placed on the prepared tooth. At least 2 minutes and 15 seconds after mixing, the excess cement was cleaned off. Following mixing, a minimum of 4 minutes and 30 seconds was allowed for the cement to set.
PURPOSE: The aim of the present, retrospective study was to describe our initial experience and early outcomes of Thulium Fiber Laser enucleation of the prostate (ThuFLEP) with the use of the FiberDust™ (Quanta System, Samarate, Italy) in patients with benign prostate hyperplasia.
METHODS: From June 2022 to April 2023, all patients who underwent endoscopic enucleation of the prostate at Urology Department of the University Hospital of Patras were included. A single surgeon utilizing the same standardized operative technique performed all the surgeries. The primary endpoints included the uneventful completion of the operation, the surgical time and any minor or major complication observed intra- or post-operatively.
RESULTS: Twenty patients with benign prostate hyperplasia were treated with ThuFLEP. All the surgeries were completed successfully and uneventfully. The enucleation phase of the operation was completed in a mean time of 45±9.1 min, while the average time needed for the morcellation was 17.65±3.42 min. No significant complications were observed intra- or post-operatively. The average hemoglobin drop was calculated to be 0.94±0.71 g/dL.
CONCLUSIONS: All the operations were successfully and efficiently completed with the use of the FiberDust™ (Quanta System, Samarate, Italy) in ThuFLEP. Significant blood loss or major complications were not observed.
Traumatic brain injury (TBI) is a major cause of morbidity and mortality globally. We unveiled the diagnostic value of serum NLRP3, metalloproteinase-9 (MMP-9) and interferon-γ (IFN-γ) levels in post-craniotomy intracranial infections and hydrocephalus in patients with severe craniocerebral trauma to investigate the high risk factors for these in patients with TBI, and the serological factors predicting prognosis, which had a certain clinical predictive value. Study subjects underwent bone flap resection surgery and were categorized into the intracranial infection/hydrocephalus/control (without postoperative hydrocephalus or intracranial infection) groups, with their clinical data documented. Serum levels of NLRP3, MMP-9 and IFN-γ were determined using ELISA kits, with their diagnostic efficacy on intracranial infections and hydrocephalus evaluated by receiver operating characteristic curve analysis. The independent risk factors affecting postoperative intracranial infections and hydrocephalus were analysed by logistic multifactorial regression. The remission after postoperative symptomatic treatment was counted. The intracranial infection/control groups had significant differences in Glasgow Coma Scale (GCS) scores, opened injury, surgical time and cerebrospinal fluid leakage, whereas the hydrocephalus and control groups had marked differences in GCS scores, cerebrospinal fluid leakage and subdural effusion. Serum NLRP3, MMP-9 and IFN-γ levels were elevated in patients with post-craniotomy intracranial infections/hydrocephalus. The area under the curve values of independent serum NLRP3, MMP-9, IFN-γ and their combination for diagnosing postoperative intracranial infection were 0.822, 0.722, 0.734 and 0.925, respectively, and for diagnosing hydrocephalus were 0.865, 0.828, 0.782 and 0.957, respectively. Serum NLRP3, MMP-9 and IFN-γ levels and serum NLRP3 and MMP-9 levels were independent risk factors influencing postoperative intracranial infection and postoperative hydrocephalus, respectively. Patients with hydrocephalus had a high remission rate after postoperative symptomatic treatment. Serum NLRP3, MMP-9 and IFN-γ levels had high diagnostic efficacy in patients with postoperative intracranial infection and hydrocephalus, among which serum NLRP3 level played a major role.
The invention relates to a gold shell coated hollow mesoporous silicon dioxide spheres, a method for preparing the same and application thereof in tumor treatment. In the gold shell coated hollow mesoporous silicon dioxide spheres, the hollow mesoporous silicon dioxide spheres or hollow mesoporous silicon dioxide spheres containing one kernel are used as cores, and the surfaces of the spheres are evenly coated with the gold shells; and the hollow mesoporous silicon dioxide spheres are filled with tumor resisting medicaments, and the surfaces of the gold shells are further coupled with specific targeting molecules of the tumor. The size of the hollow mesoporous silicon dioxide spheres and the thickness of the gold shell are controllable. According to the Mie scattering theory, the gold shells coated hollow mesoporous silicon dioxide spheres can adjust the absorption in the near infrared region and convert the light energy of the near infrared laser into the heat energy nearby to kill tumor cells. The hollow mesoporous silicon dioxide spheres can be used as controlled release carriers of therapeutic medicaments, and simultaneously the tumor specificity targeting molecules coupled on the surfaces of the gold shells make the preparation have the targeting function. The material is the multifunctional tumor resisting nanometer preparation integrating photothermal therapy, chemical therapy, high targeting and controlled release.
This prospective study includes all adults aged over 18 years of age who accept to be included in the study and provided written informed consent. All patients are under long term hemodialysis for chronic renal failure. They are subjected to a questionnaire including history of contacts with tuberculosis (TB), prior treatment for TB, history of prior tuberculin skin testing, history of BCG vaccination, country of origin, trips or prolonged stays in high incidence areas, smoking history, and medications. All patients will have a chest X-ray, and simultaneous testing with the tuberculin skin test according to the Mantoux technique, and with the T-SPOT. TB and QuantiFERON Gold in tube Interferon-gamma release assays. The study analysis agreement between tests, detection of prior TB and presumptive latent tuberculosis infection, based on these items.
BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and chemotherapy still serves as the cornerstone treatment functioning by inducing cytotoxic cell death. Notably, emerging evidence suggests that dying cell-released signals may induce cancer progression and metastasis by modulating the surrounding microenvironment. However, the underlying molecular mechanisms and targeting strategies are yet to be explored.
METHODS: Apoptotic TNBC cells induced by paclitaxel or adriamycin treatment were sorted and their released extracellular vesicles (EV-dead) were isolated from the cell supernatants. Chemokine array analysis was conducted to identify the crucial molecules in EV-dead. Zebrafish and mouse xenograft models were used to investigate the effect of EV-dead on TNBC progression in vivo.
RESULTS: It was demonstrated that EV-dead were phagocytized by macrophages and induced TNBC metastasis by promoting the infiltration of immunosuppressive PD-L1+ TAMs. Chemokine array identified CXCL1 as a crucial component in EV-dead to activate TAM/PD-L1 signaling. CXCL1 knockdown in EV-dead or macrophage depletion significantly inhibited EV-dead-induced TNBC growth and metastasis. Mechanistic investigations revealed that CXCL1EV-dead enhanced TAM/PD-L1 signaling by transcriptionally activating EED-mediated PD-L1 promoter activity. More importantly, TPCA-1 (2-[(aminocarbonyl) amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide) was screened as a promising inhibitor targeting CXCL1 signals in EVs to enhance paclitaxel chemosensitivity and limit TNBC metastasis without noticeable toxicities.
CONCLUSIONS: Our results highlight CXCL1EV-dead as a novel dying cell-released signal and provide TPCA-1 as a targeting candidate to improve TNBC prognosis.
FIELD: immunotherapy. SUBSTANCE: invention provides immunoconjugate with antitumor activity constituting monoclonal antibody or its fragment specific for human EGF receptor molecule and a specimen of chemokin family, namely interleukin-8. Preparation: DNA sequences encoding (i) antitumor activity constituting monoclonal antibody or its fragment specific for human EGF receptor molecule and (ii) biologically-active ligand are fused, complementary DNA is obtained and included into expressing vector, which is used for transformation of host cells. Transformed cells are then cultured in nutrient medium under conditions favoring expression of proposed immunoconjugate. Immunoconjugates of invention induce cytotoxic activity. EFFECT: enlarged choice of antitumor agents. 8 cl, 6 dwg
Close to 90% of people with Parkinson's disease develop voice problems during the course of the disease. These problems lead to reduced intelligibility, which entails a subsequent reduction in social participation and overall quality of life. The current study will focus on developing and pilot-testing an app to measure the intelligibility of people with PD and of healthy controls. In order to test the app's efficacy, speakers will read a set of 50 sentences that will be embedded in noise for measurement purposes. A group of listeners will also transcribe the spoken sentences to correlate their performance to that of the app. The ultimate purpose of this investigation is to improve self-monitoring and self-sufficiency in people with PD. The study is expected to last 12 months.
The present invention relates to a Chinese medicine preparation for curing hyperplasia of mamary glands and a preparation method thereof. The Chinese medicine preparation of the present invention is prepared by the uniform blending of 0.05 to 4 parts of dragon's blood and 3 to 50 parts of pangolin scale according to a weight proportion. Besides, notoginseng, sappanwood, etc. can also be added; the pangolin scales are stir-fried with table vinegar or uniformly mixed with sand, and are stir-fried until yellow and sieved for use. The Chinese medicine preparation has the advantages of reasonable prescription and convenient preparation, and has the functions of relieving the depressed liver, rectifying qi, promoting blood circulation and dissipating masses. The Chinese medicine preparation has special therapeutic effect on hyperplasia of mamary glands, and has good therapeutic effect on early mammary cancer.
The Post-High School Readiness Program helped youth build skills around identifying colleges or programs of interest, completing applications for programs, writing resumes and increasing financial literacy. The post-high school readiness curriculum was delivered by LAYC staff members and the content was delivered twice a week, for approximately 3.5 weeks (as with the intervention). For the final session, participants did not receive content and were administered the immediate post-intervention survey.
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial using non-inferior design. A total of 188 patients with breast cancer who are suitable for endocrine therapy will be enrolled into the screening period from D-28 to D-1 before administration. Eligible subjects will be randomized in a 1:1 ratio to receive LY01005 3.6 mg intramuscularly or ZOLADEX ® 3.6 mg subcutaneously once every 28 days for three doses until intolerable toxicity, disease progression requiring other anti-tumor treatments, withdrawal of consent, loss to follow-up, death or the end of the whole study, and stratified according to history of chemotherapy (yes vs. no) and age (\<45 vs. ≥45 years old). And all subjects will be also treated with tamoxifen orally twice per day (10 mg/tablet, 1 tablet/time). Blood samples will be collected at the specified time points of the study to detect serum E2, LH and FSH. Safety evaluation (including vital signs, physical examination, laboratory tests, 12 ECG, adverse events, etc.) will be conducted as required in the protocol. Additional blood samples will be collected from 12 subjects (PK subgroup) who are randomized to LY01005 group to assess the PK and PD characteristics of LY01005 in patients with breast cancer.
BACKGROUND: Volatile glucose levels after gastrectomy induce dumping syndrome, which adversely affects patient quality of life. This study aimed to evaluate the glycemic variability of proximal gastrectomy with double-tract reconstruction (PGDTR) as a function-preserving procedure.
METHODS: This study used a continuous glucose monitoring (CGM) system to record glycemic profiles of patients who underwent PGDTR or total gastrectomy (TG) and compared them. Moreover, this study evaluated postgastrectomy syndrome, including dumping symptoms, between the PGDTR and TG groups using the 37-item Postgastrectomy Syndrome Assessment Scale (PGSAS-37) questionnaire.
RESULTS: Of note, 44 patients underwent PGDTR, and 42 patients underwent TG, which included more advanced cases. CGM results showed that the SD, relative SD, and maximum drop in glucose level between 30 min and 2 h after a meal were smaller in the PGDTR group than in the TG group (14.81 vs 22.40 mg/dL [P < .001], 0.14 vs 0.20 mg/dL [P < .001], and 42.06 vs 117.67 mg/dL [P < .001], respectively). For nocturnal glucose levels, SD and percentage time below the range were smaller in the PGDTR group than in the TG group (11.76 vs 15.16 mg/dL [P = .005] and 11.25% vs 35.27% [P < .001]). The PGDTR group generally performed better than the TG group on all the PGSAS-37 questionnaire items. Patients in the PGDTR group without food inflow into the remnant stomach showed similar CGM results as those in the TG group but with stronger dumping symptoms.
CONCLUSION: Food inflow into the remnant stomach is essential for PGDTR to be a function-preserving procedure as it leads to the control of dumping symptoms and lower glucose level spikes.
One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.